Viking Therapeutics
VKTX
424 hedge funds and large institutions have $2.53B invested in Viking Therapeutics in 2025 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 115 increasing their positions, 134 reducing their positions, and 44 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
164% more call options, than puts
Call options by funds: $366M | Put options by funds: $139M
150% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 44
35% more capital invested
Capital invested by funds: $1.87B → $2.53B (+$662M)
15% more funds holding
Funds holding: 370 → 424 (+54)
0.26% more ownership
Funds ownership: 63.38% → 63.64% (+0.26%)
14% less repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 134
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$55.2M |
| 2 |
BlackRock
New York
|
+$36M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$29.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.2M |
| 5 |
Jane Street
New York
|
+$25.1M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$71.9M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$26.7M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.9M |
| 4 |
Morgan Stanley
New York
|
-$23.1M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$20M |
VKTX Hedge Fund Activity: Q4 2025 in Review
424 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2025, worth a combined $2.53B — up 35% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new VKTX positions and 44 closed out — a net gain of 66 holders — while 115 added to existing stakes and 134 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $55.2M. The largest seller was JP Morgan Chase, cutting an estimated $71.9M.
- 424 institutional investors held Viking Therapeutics (VKTX) as of Q4 2025, up from 370 in Q3 2025.
- Funds reported $2.53B of Viking Therapeutics stock for Q4 2025, up 35% quarter-over-quarter.
- 110 funds opened new Viking Therapeutics positions in Q4 2025 and 44 closed out, a net change of +66 holders.
- The largest Viking Therapeutics buyer in Q4 2025 was D.E. Shaw & Co, an estimated $55.2M added.
- The largest Viking Therapeutics seller in Q4 2025 was JP Morgan Chase, an estimated $71.9M sold.
Based on aggregated 13F filings for Q4 2025.